Company Filing History:

9 out of 1,210

Dana-Farber-Cancer Institute Inc.

patents

2 out of 517

Beth Israel Deaconess Medical Center, Inc.

Institut National De La Sante Et De La Recherche Medicale

patents

where one patent can have more than one assignee

Years Active: 2002-2025

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12258409 - Method of assessing the efficacy of a test agent for modulating programmed death 1 (PD-1) signaling by using anti-phosphotyrosinylated PD-1 monoclonal antibodies (2025-03-25),

2. 11492403 - Anti-phosphotyrosinylated programmed death 1 (PD-1) monoclonal antibodies, methods of making and methods of using thereof (2022-11-08),

3. 7700102 - Nucleic acids encoding CD100 molecules (2010-04-20),

4. 7635757 - B7-4 Antibodies and uses therefor (2009-12-22),

5. 7038013 - B7-4 polypeptides and uses therefor (2006-05-02),

6. 6936704 - Nucleic acids encoding costimulatory molecule B7-4 (2005-08-30),

7. 6576754 - CD100 antigen and uses therefor (2003-06-10),

8. 6576236 - Methods for stimulating T cell responses by manipulating a common cytokine receptor &ggr; chain (2003-06-10),

9. 6451305 - Methods for stimulating T cell responses to tumor cells expressing LFA-3 and a CD28 or CTLA4 ligand (2002-09-17),

Title: Vassiliki A Boussiotis: Innovator in Cancer Research

Introduction

Vassiliki A Boussiotis is a prominent inventor based in Brookline, MA (US). She has made significant contributions to the field of cancer research, particularly in the area of immunotherapy. With a total of nine patents to her name, her work has had a profound impact on the understanding and treatment of cancer.

Latest Patents

Among her latest patents is a method for assessing the efficacy of a test agent for modulating programmed death 1 (PD-1) signaling. This invention utilizes anti-phosphotyrosinylated PD-1 monoclonal antibodies. The discovery includes monoclonal and polyclonal antibodies that specifically bind to phosphorylated PD-1, along with immunoglobulins, polypeptides, and nucleic acids. These innovations have applications in diagnostic, prognostic, and therapeutic purposes. Another notable patent involves anti-phosphotyrosinylated programmed death 1 (PD-1) monoclonal antibodies, detailing methods of making and using these antibodies for similar applications.

Career Highlights

Vassiliki has worked with esteemed institutions such as Dana-Farber Cancer Institute Inc. and Beth Israel Deaconess Medical Center, Inc. Her research has been pivotal in advancing the understanding of immune responses in cancer treatment.

Collaborations

She has collaborated with notable colleagues, including Gordon James Freeman and Lee M Nadler, contributing to a rich environment of innovation and discovery in her field.

Conclusion

Vassiliki A Boussiotis stands out as a leading inventor in cancer research, with her patents paving the way for new therapeutic strategies. Her work continues to inspire advancements in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com